Tysabri-Associated PML Incidence

3.50

3.00
PML Incidence per 1000 patients

2.50

2.00

1.50

1.00

0.50

0.00

Clinical Trials All Post Marketing Patients Patients Treated ≥ 12 Infusions Patients Treated ≥ 18 Infusions
Patient Uptake as of: 28-Oct-09 30-Nov-09 31-Dec-09 31-Jan-10 28-Feb-10 31-Mar-10 30-Apr-10 31-May-10 30-Jun-10 31-Jul-10 2-Sep-10 1-Oct-10 2-Nov-10 28-Oct-09 30-Nov-09 31-Dec-09 31-Jan-10 28-Feb-10 31-Mar-10 30-Apr-10 31-May-10 30-Jun-10 31-Jul-10 2-Sep-10 1-Oct-10 2-Nov-10 28-Oct-09 30-Nov-09 31-Dec-09 31-Jan-10 28-Feb-10 31-Mar-10 30-Apr-10 31-May-10 30-Jun-10 31-Jul-10 2-Sep-10 1-Oct-10 2-Nov-10 28-Oct-09

High 2.80 0.57 0.63 0.67 0.73 0.83 0.89 0.92 1.00 1.03 1.09 1.14 1.15 1.21 1.01 1.09 1.15 1.23 1.39 1.47 1.51 1.62 1.65 1.73 1.80 1.80 1.87 1.23 1.29 1.31 1.42 1.63 1.72 1.77 1.92 1.93 2.00 2.09 2.09 2.17 1.98
Mid 1.00 0.38 0.43 0.47 0.52 0.62 0.67 0.70 0.77 0.80 0.85 0.90 0.91 0.96 0.68 0.76 0.81 0.89 1.03 1.10 1.14 1.24 1.27 1.35 1.42 1.42 1.49 0.79 0.86 0.89 1.00 1.18 1.27 1.32 1.46 1.47 1.54 1.63 1.63 1.71 1.26
Low 0.20 0.25 0.29 0.32 0.36 0.44 0.49 0.52 0.58 0.61 0.65 0.70 0.71 0.76 0.43 0.50 0.55 0.62 0.74 0.81 0.84 0.94 0.97 1.04 1.10 1.11 1.17 0.47 0.54 0.58 0.67 0.83 0.91 0.96 1.08 1.10 1.16 1.25 1.26 1.33 0.75

Case Location US 10 11 15 16 19 20 22 25 28 29 33
EU 19 21 24 27 27 32 32 34 36 37 38
ROW (understood to all be in Switzerland) 2 3 3 3 3 3 4 4 4 4 4
Total PML Cases 24 28 31 35 42 46 49 55 58 63 68 70 75
as of 28-Oct-09 30-Nov-09 12-Jan-09 9-Feb-10 10-Mar-10 6-Apr-10 6-May-10 7-Jun-10 2-Jul-10 4-Aug-10 2-Sep-10 1-Oct-10 2-Nov-10
Total Deaths 7 11 11 11 12 12 14 14 15

Estimated Patients in Treatment Cohort*: 37,567 38,644 39,700 40,833 41,967 43,100 43,633 44,167 44,700 45,233 45,767 48,400 49,633 26,667 28,451 30,200 31,333 32,467 33,600 34,000 34,400 34,800 35,200 35,600 37,900 38,933 16,233
Estimated PML Cases in Treatment Cohort: 24 28 31 35 42 46 49 55 58 63 68 70 75 21 24 27 31 38 43 45 50 51 54 58 62 67 20
Monthly Increase: 4 3 4 7 4 3 6 3 5 5 2 5
* Interpolated from quarterly data provided by Biogen Idec.

Q4 2007 Q1 2008 Q2 2008 Q3 2008 Q4 2008 Q1 2009 Q2 2009 Q3 2009 Q4 2009 Q1 2010 Q2 2010 Q3 2010
Current Patients End of Q: 21,300 26,000 31,800 35,500 37,700 40,000 43,300 46,000 48,400 50,300 52,800 55,100
Cummulative Patients End of Q: 36,700 43,300 48,000 48,300 52,000 56,500 60,700 64,600 67,700 71,400 75,500
ence by Treatment Duration Cohort

Patients Treated ≥ 24 Infusions Patients Treated ≥ 30 Infusions Patients Treated ≥ 36 Infusions Patients Treated ≥ 42 Infusions
30-Nov-09 31-Dec-09 31-Jan-10 28-Feb-10 31-Mar-10 30-Apr-10 31-May-10 30-Jun-10 31-Jul-10 2-Sep-10 1-Oct-10 2-Nov-10 28-Oct-09 30-Nov-09 31-Dec-09 31-Jan-10 28-Feb-10 31-Mar-10 30-Apr-10 31-May-10 30-Jun-10 31-Jul-10 2-Sep-10 1-Oct-10 2-Nov-10 28-Oct-09 30-Nov-09 31-Dec-09 31-Jan-10 28-Feb-10 31-Mar-10 30-Apr-10 31-May-10 30-Jun-10 31-Jul-10 2-Sep-10 1-Oct-10 2-Nov-10 30-Jun-10 31-Jul-10 2-Sep-10 1-Oct-10 2-Nov-10

1.96 1.93 1.91 2.19 2.21 2.22 2.36 2.28 2.32 2.43 2.42 2.53 2.65 1.99 1.88 1.92 2.28 2.37 2.24 2.25 2.17 2.07 2.25 2.22 2.24 3.14 2.28 1.79 1.81 1.80 2.04 1.78 1.75 1.73 1.70 1.79 1.74 1.77 2.74 2.65 2.75 2.69 2.53
1.28 1.29 1.29 1.55 1.59 1.62 1.76 1.71 1.76 1.86 1.87 1.97 1.44 1.05 1.02 1.10 1.42 1.53 1.47 1.50 1.46 1.40 1.58 1.57 1.61 0.87 0.63 0.50 0.62 0.70 0.94 0.82 0.85 0.88 0.90 1.00 1.00 1.06 1.07 1.14 1.34 1.36 1.33
0.79 0.82 0.84 1.06 1.11 1.14 1.28 1.25 1.30 1.40 1.41 1.51 0.69 0.48 0.49 0.57 0.83 0.94 0.91 0.95 0.93 0.91 1.07 1.08 1.12 0.11 0.08 0.06 0.13 0.19 0.34 0.30 0.34 0.38 0.41 0.50 0.52 0.58 0.29 0.37 0.54 0.59 0.61

17,479 18,700 20,100 21,500 22,900 24,033 25,167 26,300 27,433 28,567 29,400 30,433 8,667 9,643 10,600 11,633 12,667 13,700 14,400 15,100 15,800 16,500 17,200 19,700 21,000 4,053 4,410 4,760 5,440 6,120 6,800 7,400 8,000 8,600 9,200 9,800 11,500 12,467 3,500 4,100 4,700 5,400 6,050
22 24 26 33 36 39 44 45 48 53 55 60 12 10 11 13 18 21 21 23 23 23 27 31 34 3 3 2 3 4 6 6 7 8 8 10 12 13 4 5 6 7 8